TickerTalks
Browse all tickers →
TickerTalks›$ARWR
ARARWR

Arrowhead Pharmaceuticals, Inc.

$ARWR·Biotechnology·Healthcare
$74.52+4.0%
Mentions · last 7 days
2026-07-14: 15 posts2026-07-15: 14 posts2026-07-16: 9 posts2026-07-17: 9 posts2026-07-18: 4 posts2026-07-19: 3 posts2026-07-20: 5 posts59
Price updated 23m ago·X counts updated 23h ago
ARARWR
$ARWRArrowhead Pharmaceuticals, Inc.
$74.52+4.01%59 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ARWR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-07-21

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Arrowhead Pharmaceuticals has REDEMPLO EU authorization plus Aug 6 earnings — the RNAi platform pivot to commercial-scale.

Arrowhead Pharmaceuticals is a biotech developing RNA interference (RNAi) therapies for complex diseases — cardiometabolic pipeline plus approved products in FCS. The bundle has limited price/fundamental history but a specific product-approval catalyst.

  • REDEMPLO (plozasiran) EU marketing authorization is a real commercial-scale signal: approval for familial chylomicronemia syndrome means Arrowhead is transitioning from pure-pipeline to commercial operator in Europe.
  • Cohen board appointment adds a strategic-planning voice: Managing Director appointed as a specific governance-and-capital-allocation signal.
  • Cardiometabolic pipeline discussion plus R&D webinar series is real strategic communication: management actively engaging means specific pipeline detail is expected Aug 6.
  • Bullish analyst initiation reported July 14 is a sell-side rerating signal alongside takeover-target framing in specialized biotech coverage.
  • Consensus Aug 6 EPS -$1.19 reflects continued clinical-stage cash burn — REDEMPLO commercial launch has to convert to real revenue for the equity thesis to compound.

Aug 6 print with REDEMPLO EU launch progression plus cardiometabolic pipeline detail pulls ARWR toward the sell-side reset zone. A soft pipeline update or continued dilution extends the setup — RNAi platform is genuine but multi-year translation from EU-approval to sustained commercial revenue requires specific execution progression.

What to watch: Aug 6 Q3 FY26 earnings — REDEMPLO EU launch progression plus cardiometabolic pipeline detail pulls ARWR toward sell-side reset zone; a soft pipeline update or continued dilution extends the setup — RNAi platform is genuine but multi-year translation requires specific execution progression.

On the calendar: 2026-08-06 — Q3 FY26 earnings

insufficient history

Read the AI verdict + X sentiment for $ARWR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ARWR.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

Top industry ETF

$IBBiShares Biotechnology ETF
+9.9%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.93$-1.09+14.7%
Q4 2025Feb 5, 2026$0.22$0.60-63.3%
Q3 2025Nov 25, 2025$-0.18$-0.11-61.3%
Q2 2025Aug 7, 2025$-1.26$-0.94-34.0%
Next earningsThu, Aug 6·consensus EPS $-1.19

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.—Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.—Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 122.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.265-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 173
AI summary

Matthew Gregory Cohen filed a Form 3 as a newly appointed Director of Arrowhead Pharmaceuticals, Inc. (ARWR), effective June 15, 2026, reporting 0 shares of common stock and no derivative securities beneficially owned. Routine insider ownership disclosure accompanying his board appointment with no financial or operational impact.

8-KOfficer or director changeJun 168-K — Item 5.02: Officer or director change
AI summary

Arrowhead Pharmaceuticals, Inc. (ARWR) appointed Dr. Matt Cohen, M.D., M.B.A. to its Board of Directors effective June 12, 2026, with standard non-employee director compensation and equity awards. Cohen is Managing Director at Vida Ventures and brings 25+ years of healthcare investing experience, including nearly two decades as lead portfolio manager of the JP Morgan Global Healthcare Fund and co-PM of the JP Morgan Small Cap Growth Fund, plus prior roles at healthcare hedge funds and as a surgery resident. Routine but value-adding board appointment adding deep public biotech investment expertise.

8-KShareholder voteMar 208-K — Item 5.07: Shareholder vote
+ 13 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com·8d agoArrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcriptseekingalpha.com·22d ago3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree247wallst.com·27d agoArrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)businesswire.com·29d agoArrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinarsbusinesswire.com·34d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$MRNA$ATAI$ALLO$QTTB$AGEN$IOVA$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport